Pyxis Diagnostics
Ilan Volovitz is an accomplished researcher and entrepreneur, currently serving as the Head of the Cancer Immunotherapy Lab at Tel Aviv Medical Center since September 2007, where the focus lies on the immunology of brain tumors. In addition, Volovitz is the Chief Scientist and Founder of Pyxis Diagnostics. Prior experience includes roles as CIO at Smartap and Founder and CEO of SMB-Israel. An academic background includes a PhD and MSc in Tumor Immunology from The Weizmann Institute of Science, supplemented by a BSc in Biology from Tel Aviv University.
Previous companies
This person is not in any teams
This person is not in any offices
Pyxis Diagnostics
Immunotherapy revolutionized the treatment of many malignancies. However, many patients fail to respond to immuno-oncology (IO) drugs, although satisfying the accepted clinical criteria for IO treatment. This stems partially from the very incomplete understanding of the network-level interactions between various cells within the tumor itself, which together determine the fate of the anti-cancer immune responses. Using a novel, high-resolution method to resolve all the cells that together comprise the tumour micro-environment, we are able to infer important inter-cellular connections that may protect the tumor from an immune assault. By combining many patient tumor-immune networks, we at Pyxis, can predict IO drug response for many cancer types. Our platform can also suggest alternative treatment routes in cases where the predicted drug response is low, improving the quality of life of oncological patients.